Abstract
The examination of the biological roles of ruthenium complexes as well as the possibility of producing ruthenium-based drugs, active in the treatment of human malignancies, is believed to have begun with the discovery of the antineoplastic activity of cis-dichlorodiammine platinum(II) (hereafter called cisplatin). The fate of ruthenium compounds is common to that of many other transition metals. Based on the elementary observation that ruthenium belongs to the Group VIII transition metals (the so-called platinum group), ruthenium compounds have been studied in comparison to cisplatin in order to ameliorate cisplatin toxicity and potency. In other words, like palladium, rhodium, iridium, osmium and other transition metals, ruthenium was studied in order to obtain compounds which are more potent than cisplatin and under the same conditions in which cisplatin is active. Therefore, from most investigations it is expected that ruthenium compounds will reduce tumour growth by a mechanism of interaction with cell DNA, similar to that shown by cisplatin. Nevertheless, an accurate examination of the literature on ruthenium compounds reveals that these metal-based antitumour drugs show a number of differences from cisplatin, particularly when tumour sensitivity and the effects of tumour reduction on host survival time are concerned. It thus appears that ruthenium compounds can have a selected place in therapy, different from that of cisplatin, and can represent a tool for investigating antitumour chemotherapy and for opening a new direction in the development of a new generation of anticancer agents.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bregant, F., Pacor, S., Ghosh, S. (1993) Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Anticancer Res., 13, 1007–1010.
Cauci, S., Alessio, E., Mestroni, G. and Quadrifoglio, F. (1987) Reaction of cis-RuII(DMSO)4Cl2 with DNA and with some of its bases in aqueous solution. Inorg. Chim. Acta, 137, 19–24.
Chan, P. K. L., Skov, K. A., James, B. R. and Farrell, N. P. (1986) A new ruthenium radiosensitizer: RuCl2(DMSO)2(4-nitroimidazole)2. Int. J. Rad. Oncol. Biol. Phys., 12, 1059–1062.
Clarke, M. J. (1980) Oncological implications of the chemistry of ruthenium, in Metal Ions in Biological Systems, (ed. H. Sigel), Vol. 11, Marcel Dekker, New York, pp. 231–283.
Clarke, M. J. (1989) Ruthenium chemistry pertaining to the design of anticancer agents, in Progress in Clinical Biochemistry and Medicine-Non-platinum Metal Complexes in Cancer Chemotherapy(ed. M. J. Clarke), Springer-Verlag, Berlin, pp. 25–39.
Clarke, M. J., Galang, R. D., Rodriguez, V. M. et al. (1988) Chemical considerations in the design of ruthenium anticancer agents, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy(ed. M. Nicolini), Martinus Nijhoff Publishing, Boston, pp. 582–600.
Coluccia, M., Sava, G., Loseto, F. et al. (1993) Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline. Eur. J. Cancer, 29A, 1873–1879.
Denekamp, J. (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metast. Rev., 9, 267–282.
Durig, J. R., Danneman J., Behnke, W. D. and Mercer, E. E. (1976) The induction of filamentous growth in Escherichia coli by ruthenium and palladium complexes. Chem. Biol. Interact., 13, 287–294.
Farrell, N. (1983) Chemical and biological activity of metal complexes containing dimethylsulfoxide, in Chemistry and Biochemistry of Platinum, Gold and Other Chemotherapeutic Agents (ed. S. J. Lippard), ACS Symposium Series, American Chemical Society, Washington, Vol. 209, pp. 279–297.
Fruhauf, S. and Zeller, W. J. (1991) In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and-resistant rat ovarian tumours. Cancer Chemother. Pharmacol., 27, 301–307.
Gagliardi, R., Sava, G., Pacor, S. et al. (1994) Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse. Clin. Exp. Metast., 12, 93–100.
Garzon, F. T., Berger, M. R., Keppler, B. K. and Schmahl, D. (1987) Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors. Cancer Chemother. Pharmacol., 19, 347–349.
Gilbert, I. G. F. and Radley, J. M. (1964) The uptake of radioactive ruthenium by rat liver nuclei. Biochim. Biophys. Acta, 79, 568–574.
Giraldi, T., Sava, G., Bertoli, G. et al. (1977) Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloroplati-num(II). Cancer Res., 37, 2662–2666.
Heppner, G. H. and Miller, B.E. (1983) Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metast. Rev., 2, 5–24.
Kelly, J. M, Feeney, M. M., Tossi, A. B. et al. (1990) Interaction of tetra-azaphenanthrene ruthenium complexes with DNA and oligonucleotides. A photophysical and photochemical investigation. Anti-Cancer Drug Des., 5, 69–75.
Kelman, A. D., Clarke, M. J., Edmonds, S. D. and Peresie, H. J. (1977) Biological activity of rutheniumpurine complexes. J. Clin. Hematol. Oncol., 7, 274–288.
Keppler, B. K. and Rupp, W. (1986) Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate(III). J. Cancer Res. Clin. Oncol., 111, 166–168.
Keppler, B. K., Balzer, W. and Scifried, V. (1987) Synthesis and antitumor activity of triazolium-bis (triazole) tetrachlororuthenate(III) and bistria-zolium-triazolepentachlororuthenate(III). Arzneimittelforsch./Drug Res., 37, 770–771.
Keppler, B. K., Wehe, D., Endres, H. and Rupp, W. (1978a) Synthesis, antitumor activity, and X-ray structure of bis(imidazolium)(imidazole) penta-chlororuthenate(III), (ImH)2(RuIm-Cl5). Inorg. Chem., 26, 844–846.
Keppler, B. K., Rupp, W., Juhl, U. M. et al. (1987b) Synthesis, molecular structure, and tumor inhibiting properties of imidazolium trans-bis (imidazole) tetrachlororuthenate(III) and its methyl-substituted derivatives. Inorg. Chem., 26, 4366–4370.
Keppler, B. K., Henn, M., Juhl, U. M. et al. (1989) New ruthenium complexes for the treatment of cancer, in Progress in Clinical Biochemistry and Medicine-Non-platinum Metal Complexes in Cancer Chemotherapy (ed. M. J. Clarke), Springer-Verlag, Berlin, pp. 41–69.
Kreuser, E. D., Keppler, B. K., Berdel, W. et al. (1991) Antitumor activity of new ruthenium compounds and their modulation by cytokines in human colon carcinoma cell lines (CCCL). Proceedings of the Annual Meeting of the American Association for Cancer Research, 32, A2283.
Loseto, F., Mestroni, G., Lacidogna, G. et al. (1991) Interaction of RuCl2(di-methylsulphoxide)4 isomers with DNA. Anticancer Res., 11, 1549–1554.
Mestroni, G., Alessio, E., Calligaris, M. et al. (1989) Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide, in Progress in Clinical Biochemistry and Medicine-Non-platinum Metal Complexes in Cancer Chemotherapy (ed. M. J. Clarke), Springer-Verlag, Berlin, pp. 71–87.
Monti-Bragadin, C., Tamaro, M. and Banfi, L. (1975) Mutagenic activity of platinum and ruthenium complexes. Chem. Biol. Interact., 11, 469–472.
Monti-Bragadin, C., Ramani, L., Samer, L. et al. (1975) Effects of cis-dichlorodiammineplatinum(II) and related transition metal complexes on Escherichia coli. Antimicrob. Agents Chemother., 7, 825–827.
Pacor, S., Sava, G., Ceschia, V. et al. (1991) Antineoplastic effects of mer-trichlorobisdimethylsulfoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. Chem. Biol Interact., 78, 223–234.
Puccetti, P., Romani, L. and Fioretti, M. C. (1987) Chemical xenogenization of experimental tumors. Cancer Metast. Rev., 6, 93–112.
Pyle, A. M., Rehmann, J. P., Meshoyrer, R. et al. (1989) Mixed-ligand complexes of ruthenium(II): factors governing binding to DNA. J. Am. Chem. Soc., 11, 3051–3058.
Rosenberg, B., Renshaw, E., Vancamp, L. et al. (1967) Platinum-induced filamentous growth in Escherichia coli. J. Bacteriol., 93, 716–721.
Sava, G., Giraldi, T., Mestroni, G. and Zassinovich, G. (1983) Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiamminoplatinum(II) in mice bearing Lewis lung carcinoma Chem. Biol. Interact., 45, 1–6.
Sava, G., Zorzet, S., Giraldi, T. et al. (1984) Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur. ]. Cancer Clin. Oncol., 20, 841–847.
Sava, G., Giraldi, T., Perissin, L. et al. (1987) Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. Clin. Exp. Metast., 1, 27–34.
Sava, G., Pacor, S., Ceschia, V. et al. (1989a) trans-Ru (II) dimethylsulphoxides: antineoplastic action on mouse tumours. Pharmacol Res., 21, 453–454.
Sava, G., Pacor, S., Zorzet, S. et al(1989b) Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system. Pharmacol Res., 21, 617–628.
Sava, G., Zorzet, S., Pacor, S. et al. (1989c) Effects of two pyridinalalkylimine-rhodium(I) complexes in mice bearing MCa mammary carcinoma. Cancer Chemother. Pharmacol, 24, 302–306.
Sava, G., Pacor, S., Bregant, F. et al. (1990) Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulfoxide)4. Pharmacology (Life Science Advances), 9, 79–84.
Sava, G., Pacor, S., Mestroni, G. and Alessio, E. (1992a) Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]0 and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors. Anti-Cancer Drugs, 3, 25–31.
Sava, G., Pacor, S., Mestroni, G. and Alessio, E. (1992b) Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin. Exp. Metast., 10, 273–280.
Singh, S. M., Suresh, A., Basu, S. and Sohdi, A. (1991) In vitro activation of murine bone marrow-derived macrophages with cisplatin, lipopolysaccharide and mitomycin-C. Anti-Cancer Drug Des., 6, 299.
Sohdi, A., Pai, K., Singh, S. M. et al. (1991) Effect of cisplatin on the activation of human NK cells, monocytes and generation of lymphokine activated killer (LAK) cells in vitro. Anti-Cancer Drug Des., 6, 300.
Som, P., Oster, Z. H., Matsui, K. et al. (1983) 97 Ru-transferrin uptake in tumor and abscess. Eur. ]. Med., 8, 491–494.
Srivastava, S. C., Mausner, L. F. and Clarke, M. J. (1989) Radioruthenium-labeled compounds for diagnostic tumor imaging, in Progress in Clinical Biochemistry and Medicine-Non-Platinum Metal Complexes in Cancer Chemotherapy (ed. M. J. Clarke), Springer-Verlag, Berlin, pp. 111–150.
Srivastava, S. C., Richards, P., Meinken, G. E. et al. (1981) Tumor uptake of radioruthenium compounds, in Radiopharmaceuticals: Structure Activity Relationship (ed. R. Spencer), Grune and Stratton, New York, pp. 207–223.
Talmadge, J. E. (1983) The selective nature of metastasis. Cancer Metast. Rev., 2, 25–40.
Tanabe, M. and Yamamoto, G. (1975) 97Ru and 103Ru in subcutaneous tumor in rodents. Ada Med. Okayama, 29, 431–436.
Waters, S. L. (1983) Potential medical applications of ruthenium isotopes. Coord. Chem. Rev., 52, 171–182.
Yasbin, R. E., Matthews, C. R. and Clarke, M. J. (1980) Mutagenic and toxic effects of ruthenium. Chem. Biol. Interact., 31, 355–365.
Zorzet, S., Perissin, L., Piccini, P. et al. (1989) Tumor metastatic potential after treatment with selective antimetastatic drugs. Pharmacol. Res., 21, 457–459.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Sava, G. (1994). Ruthenium compounds in cancer therapy. In: Fricker, S.P. (eds) Metal Compounds in Cancer Therapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1252-9_4
Download citation
DOI: https://doi.org/10.1007/978-94-011-1252-9_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4545-2
Online ISBN: 978-94-011-1252-9
eBook Packages: Springer Book Archive